154 related articles for article (PubMed ID: 31966643)
1. Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer.
Kim EY; Lee KH; Yun JS; Park YL; Park CH; Do SI; Chae SW
Int J Clin Exp Pathol; 2017; 10(7):7929-7939. PubMed ID: 31966643
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor status is highly conserved during tumor progression of breast cancer.
Grogg A; Trippel M; Pfaltz K; Lädrach C; Droeser RA; Cihoric N; Salhia B; Zweifel M; Tapia C
BMC Cancer; 2015 Nov; 15():872. PubMed ID: 26552477
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor expression in triple negative breast carcinoma and its association with the clinicopathological parameters.
Teoh PY; Tan GC; Mahsin H; Wong YP
Malays J Pathol; 2019 Aug; 41(2):125-132. PubMed ID: 31427547
[TBL] [Abstract][Full Text] [Related]
5. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
Riaz N; Idress R; Habib S; Lalani EN
Front Oncol; 2020; 10():1083. PubMed ID: 32850312
[No Abstract] [Full Text] [Related]
6. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.
Astvatsaturyan K; Yue Y; Walts AE; Bose S
PLoS One; 2018; 13(6):e0197827. PubMed ID: 29883487
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor and enzymes in lymph node metastasis and cancer reoccurrence in triple-negative breast cancer.
McNamara KM; Yoda T; Miki Y; Nakamura Y; Suzuki T; Nemoto N; Miyashita M; Nishimura R; Arima N; Tamaki K; Ishida T; Ohuchi N; Sasano H
Int J Biol Markers; 2015 May; 30(2):e184-9. PubMed ID: 25588857
[TBL] [Abstract][Full Text] [Related]
8. Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation.
McNamara KM; Yoda T; Miki Y; Chanplakorn N; Wongwaisayawan S; Incharoen P; Kongdan Y; Wang L; Takagi K; Mayu T; Nakamura Y; Suzuki T; Nemoto N; Miyashita M; Tamaki K; Ishida T; Ohuchi N; Sasano H
Cancer Sci; 2013 May; 104(5):639-46. PubMed ID: 23373898
[TBL] [Abstract][Full Text] [Related]
9. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
Abd-Elazeem MA; Abd-Elazeem MA
Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
[TBL] [Abstract][Full Text] [Related]
10. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer.
Shen Y; Yang F; Zhang W; Song W; Liu Y; Guan X
Cell Physiol Biochem; 2017; 43(5):2047-2061. PubMed ID: 29059676
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis.
Wang C; Pan B; Zhu H; Zhou Y; Mao F; Lin Y; Xu Q; Sun Q
Oncotarget; 2016 Jul; 7(29):46482-46491. PubMed ID: 27374089
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.
Zuo T; Wilson P; Cicek AF; Harigopal M
Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579
[TBL] [Abstract][Full Text] [Related]
14. Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer.
Asano Y; Kashiwagi S; Goto W; Tanaka S; Morisaki T; Takashima T; Noda S; Onoda N; Ohsawa M; Hirakawa K; Ohira M
Cancers (Basel); 2017 Jan; 9(1):. PubMed ID: 28067809
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes.
Rammal R; Goel K; Motanagh SA; Carter GJ; Clark BZ; Fine JL; Harinath L; Villatoro TM; Yu J; Bhargava R
Mod Pathol; 2024 May; 37(7):100517. PubMed ID: 38763422
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria.
Haruna M; Daramola AO; Awolola NA; Badr NM; Banjo AAF; Shaaban A
Ecancermedicalscience; 2022; 16():1452. PubMed ID: 36405944
[TBL] [Abstract][Full Text] [Related]
17. Expression of androgen receptor in invasive ductal breast carcinomas: a clinicopathological study from Jordan.
Obeidat FN; Ahram M; Al-Khader A; Mbaideen SA; Hassan H; Altarawneh B; Battah K
Ann Saudi Med; 2018; 38(5):326-335. PubMed ID: 30284987
[TBL] [Abstract][Full Text] [Related]
18. Incidence and Prognostic Significance of Androgen Receptors (AR) in Indian Triple-Negative Breast Cancer (TNBC).
Mishra A; Mishra SK; Sharanappa V; Krishnani N; Kumari N; Agarwal G
Indian J Surg Oncol; 2024 Jun; 15(2):250-257. PubMed ID: 38741650
[TBL] [Abstract][Full Text] [Related]
19. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
20. Expression and clinical significance of androgen receptor in triple negative breast cancer.
Luo X; Shi YX; Li ZM; Jiang WQ
Chin J Cancer; 2010 Jun; 29(6):585-90. PubMed ID: 20507730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
